期刊文献+

心源性恶病质患者生长激素、胰岛素、胰岛素样生长因子1信号的变化 被引量:3

The Change of Growth Hormone,Insulin-like Growth Factor-1,and Insulin Signal in Cardiac Cachexia
下载PDF
导出
摘要 心源性恶病质是慢性充血性心力衰竭发展到后期的一个不可逆过程。它的特点是新陈代谢、炎症、内分泌途径的重构。胰岛素、生长激素和胰岛素样生长因子1(IGF-1)参与葡萄糖,蛋白质和脂类的新陈代谢过程,调节机体构成。心源性恶病质患者体内的上述三个信号受损,导致合成/分解代谢失衡。该文就近年来国内外对心源性恶病质患者生长激素、胰岛素、IGF-1信号的变化、发生机制及细胞因子对其调控的研究进行综述,以期为日后心源性恶病质的治疗提供理论依据。 Cardiogenic cachexia is an irreversible process that develops at the end stage ot chronic congestive heart failure. It is characterized by the remodeling of the metabolic, inflammatory, and endocrine pathways. Insulin, growth hormone, and insulin-like growth factor 1 (IGF-1) are involved in glucose, protein, and fat metabolism, which regulates body composition. In cardiogenic cachexia, the above three signals are impaired which causes anabolic/catabolic imbalance. Here is to make a review of the research on growth hormone, insulin, IGF-1 signal changes and mechanisms and cytokines regulation in patients with cardiac cachexia, to provide theoretical refer- ences for the future treatment.
作者 樊勤梅 张昕
出处 《医学综述》 2014年第7期1158-1160,共3页 Medical Recapitulate
关键词 心源性恶病质 胰岛素 生长激素 胰岛素样生长因子1 信号通路 Cardiogenic cachexia Insulin Growth hormone Insulin-like growth factor 1 Signaling pathway
  • 相关文献

参考文献22

  • 1Trobec K,von Haehling S, Anker SD,找 al. Growth hormone,insu-lin-like growth factor 1,and insulin signaling-a pharmacologicaltarget in body wasting and cachexia [J]. Cachexia SarcopeniaMuscle,2011,2(4) :191-200.
  • 2Muscaritoli M,Anker SD, Argil6s Jyet al. Consensus definition ofsarcopenia,cachexia and precachexia:joint document elaborated bySpecial Interest Groups (SIG) 11 cachexia-anorexia in chronic wast-ing diseases" and " nutrition in geriatrics" [J]. Clin Nutr,2010,29(2):154-159.
  • 3叶小帆,徐晨光.心源性恶液质的机制研究进展[J].现代医药卫生,2009,25(8):1177-1179. 被引量:1
  • 4Palus S,Schur R,Akashi YJ,et al. Ghrelin and its analogues,BIM-28131 and BIM-28125, improve body weight and regulate theexpression of MuRF-1 and maft>x in a ratheart failure model [J].PLoS One,2011,6(11) :l-2.
  • 5Ottosson M,Lonnroth P, Bjomtorp P,et al. Effects of cortisol andgrowth hormone on lipolysis in human adipose tissue [J] . J ClinEndocrinol Metas, 2000,85 (2) ; 799-803.
  • 6Previs SF,Withers DJ,Ren JM,et al. Contrasting effects of IRS-1versus IRS-2 gene disruption on carbohydrate and lipid metabolismin vivo[J]. J Biol Chem,2000,275(50) :38990-38994.
  • 7Kido Y, Nakae J, Accili D. The insulin receptor and its celluartargets[J]. J Clin Endocr Metab,2001,86(3) :972-979.
  • 8Laurizen HP, Galbo H, Toyoda T, et al. Kinetics of contraction-induced GLUT4 translocation in skeletal muscle fibers from livingmice[J]. Diabetes,2010,59(9) :2133-2144.
  • 9Chang L,Chiang SH,Saltiel AR. Insulin signaling and the regula-tion of glucose transport[J]. Mol Med,2004,10(7/12) :65-71.
  • 10Nielsen C,Gormsen LC,Jessen N,ei al. Growth hormone signalingin vivo human muscle and adipose tissue : impact of insulin,sub-strate background, and growth hormone receptor blockade [J]. JClin Endocrin Metab,2008,93(7) :2842-2850.

二级参考文献40

  • 1Anker SD, Coats AJS.Cardiac cachexia :a syndrome with impaired survival and immune and neuroendocrine aetivation[J].Chest, 1999, 115:836.
  • 2King D, Smith ML,Chapman TJ ,et al.Fat malabsorption in elderly patients with cardiac cachexia[J].Age Ageing, 1996,25 : 144.
  • 3Anker SD ,Chua TP,Ponikowski P,et al.Hormonal changes and eatabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia[J].Circulation, 1997,96:526.
  • 4Harrington D,Anker SD ,Chua TP,et al.Skeletal muscle function and its relation to exercise tolerance in chronic heart failure[J].Am Coil Cardiol, 1997,30:1758.
  • 5Vescovo G,Serafini F,Facchin L,et al.Specific changes in skeletal muscle myosin heavychains composition in cardiac failure:differences compared with disuse atrophy as assessed on nficrobiopsies by high resolution electrophoresis[J].Heart, 1996,76 : 337.
  • 6Berry C ,Clark AL.Catabolism in chronic heart failure[J].Eur Heart J, 2000,21:521.
  • 7Yoshizumi M ,Perrella MA.Bumett JC .et al.Tumor necrosis factordownregulates an endothelial nitric oxide synthase mRNA by shortening its half-life[J].Circ Res, 1993,73:205.
  • 8Levine B,Kalman J ,Mayer L,et al.Elevated circulating levels of tumor necrosis factor in severe chronic heart failure[J].N Engl J Med, 1990,323:236.
  • 9Barton BE.IL-6:insights into novel biological activities[J]. Clin lmmunol Immunopathol, 1997,85 : 16.
  • 10Langhans W. Hnlpka B.Interleukins and tumor necrosis factor as inhibitors of food intake[J].Neuropeptides, 1999,33:415.

共引文献4

同被引文献21

引证文献3

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部